



UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/061,128
Appl. : Schinazi *et al.*
Filed : January 30, 2002
TC/A.U. : 1637
Examiner : Jezia Riley

Confirmation No. 1763

Docket No. : 18085.105232 (EMU 2000 CIP)
Customer No. : 20786

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

May 27, 2004

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed. The Commissioner is authorized to charge any required fees for submission of an Information Disclosure Statement to Deposit Account No. 11-0980.

Respectfully submitted,



Sherry M. Knowles, Esq.

Registration No. 33,052

w/express permission
Susanne Hollnager
Reg. No. 57,811

King & Spalding
191 Peachtree Street, N.E.
Atlanta, Georgia 30303
404-572-3541
404-572-5145 fax



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

1

Complete if Known

Application Number	10/061,128
Filing Date	January 30, 2002
First Named Inventor	Schinazi, et al.
Group Art Unit	1637
Examiner Name	
Attorney Docket Number	18085.105232 (EMU2000CIPCON)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	AA	SCHINAZI, et al., "Selective Inhibition of Human Immunodeficiency viruses by Racemates and Enantiomers of cis-5-Fluoro-1-2[Hydroxymethyl]-1, 3-Oxathiolane-5-yl]Cytosine" <i>Antimicrobial Agents and Chemotherapy</i> , November 1992, pp. 2423-2431.	
	AB	MARQUEZ, V.E., et al., <i>Nucleosides & Nucleotides</i> , 14(3-5), 555-558 (1995)	
	AC	SIDDIQUI MA et al., <i>Tetrahed. Letters</i> , vol. 39 no. 13 26 March 1998.	
	AD	WANTANABE, et al., "Synthesis and Anti-HIV Activity of 2'-"Up"-Fluoro Analogues of Active Anti-Aids Nucleosides 3'- Azido-3'deoxythymidine (AZT) and 2', 3'- dideoxycytidine (DDC)," <i>J. Med. Chem.</i> 1990, 33, 2145-2150.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.